Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?

被引：2

作者：

Vidal-Cevallos, Paulina ^{[1
]}

Chavez-Tapia, Norberto ^{[1
]}

机构：

[1] Med Clin & Foundation, Obes & Digest Dis Unit, Puente Piedra 150, Mexico City 14050, Mexico

来源：

MED | 2024年 / 5卷 / 05期

关键词：

D O I：

10.1016/j.medj.2024.03.013

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The most important factor associated with liver -related mortality in NAFLD is liver fibrosis. There is no approved treatment for metabolic dysfunction -associated steatohepatitis (MASH) or liver fibrosis. In the MAESTRO-NASH trial, Harrison et al. 1 demonstrated the efficacy of resmetirom, a selective THR- 8 agonist, for the treatment of MASH and liver fibrosis at 52 weeks.

引用

页码：375 / 376

页数：2

共 50 条

[1] Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2024, 66 (1701):
[2] Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
Loomba, Rohit
Hartman, Mark L.
Lawitz, Eric J.
Vuppalanchi, Raj
Boursier, Jerome
Bugianesi, Elisabetta
Yoneda, Masato
Behling, Cynthia
Cummings, Oscar W.
Tang, Yuanyuan
Brouwers, Bram
Robins, Deborah A.
Nikooie, Amir
Bunck, Mathijs C.
Haupt, Axel
Sanyal, Arun J.
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04): : 299 - 310
[3] Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis
Saeed, Anzel
Rai, Kuldeep Dalpat
Saeed, Muzammil
LIVER RESEARCH, 2024, 8 (03) : 193 - 194
[4] Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease
Lurje, Isabella
Tacke, Frank
HEPATOBILIARY SURGERY AND NUTRITION, 2024, 13 (06) : 1034 - 1037
[5] Metabolic Dysfunction-Associated Steatohepatitis and Cardiovascular Disease Prevention: Is Resmetirom Useful?
Borozan, Sanja
Vujosevic, Snezana
Mikhailidis, Dimitri P.
Muzurovic, Emir
CURRENT VASCULAR PHARMACOLOGY, 2025, 23 (01) : 4 - 7
[6] Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
Kokkorakis, Michail
Boutari, Chrysoula
Hill, Michael A.
Kotsis, Vasilios
Loomba, Rohit
Sanyal, Arun J.
Mantzoros, Christos S.
METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 154
[7] Early experience with resmetirom to treat metabolic dysfunction-associated steatohepatitis with fibrosis in a real-world setting
Ravela, Neel
Shackelford, Phoebe
Blessing, Nadia
Yoder, Lindsay
Chalasani, Naga
Samala, Niharika
HEPATOLOGY COMMUNICATIONS, 2025, 9 (04)
[8] Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide
Huang, Rui
Zhang, Chunli
Mo, Xiaodong
Rao, Huiying
CHINESE MEDICAL JOURNAL, 2025, 138 (02) : 127 - 129
[9] Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide
Huang Rui
Zhang Chunli
Mo Xiaodong
Rao Huiying
中华医学杂志英文版, 2025, 138 (02)
[10] Protective hepatocyte signals restrain liver fibrosis in metabolic dysfunction-associated steatohepatitis
Steffani, Marcella
Geng, Yana
Pajvani, Utpal B.
Schwabe, Robert F.
JOURNAL OF CLINICAL INVESTIGATION, 2024, 134 (07):

← 1 2 3 4 5 →